Coherus Oncology (CHRS) Inventory (2018 - 2026)

Coherus Oncology has disclosed Inventory across 9 years of filings, most recently posting $4.8 million for Q1 2026.

• Inventory for Q1 2026 came in at $4.8 million, up 37.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (up 37.15% YoY), and the FY2025 annual result was $3.2 million, down 24.6% from the prior year.
• Inventory came in at $4.8 million for Q1 2026 at Coherus Oncology, up from $3.2 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $66.8 million in Q3 2023 to a low of $2.0 million in Q3 2025.
• The 5-year median for Inventory is $36.9 million (2022), against an average of $33.6 million.
• Across the five-year window, Inventory surged 140.93% in 2023 and tumbled 95.7% in 2025, its largest moves.
• Coherus Oncology's Inventory stood at $38.8 million in 2022, then soared by 61.39% to $62.6 million in 2023, then tumbled by 93.28% to $4.2 million in 2024, then retreated by 24.6% to $3.2 million in 2025, then soared by 52.11% to $4.8 million in 2026.
• The last three Inventory figures came in at $4.8 million (Q1 2026), $3.2 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.